Klaus Pors

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Venues

Biomedicines

Cancers

RSC pharmaceutics

Journal of medicinal chemistry

University of Bradford

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Bradford Sep 01 2013

United Kingdom

Senior Lecturer in Chemical Biology :: Institute of Cancer Therapeutics

University of Bradford May 01 2005 - Aug 31 2013

United Kingdom

Yorkshire Cancer Research Lecturer in Medicinal Chemistry & Team Leader :: Institute of Cancer Therapeutics

University of Bradford Feb 01 2005 - Aug 31 2005

United Kingdom

Post-Doctoral Research Assistant in Synthetic and Medicinal Chemistry :: Institute of Cancer Therapeutics

UCL School of Pharmacy Feb 01 2002 - Jan 31 2005

United Kingdom

Post-Doctoral Research Assistant in Synthetic and Medicinal Chemistry :: Department of Pharmaceutical and Biological Chemistry

Publications

Enric Arasanz Picher, Wahajuddin Muhammad, Stefan Barth, Julia C Chisholm, Janet Shipley, Klaus Pors
The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma. Cancers 16 (5) (2024)
Abdullahi Magaji Dauda, Thomas Swift, Richard Telford, Hend A A Abd El-Wahab, Chhanda Charan Danta, Klaus Pors, Amalia Ruiz
Insight into the liposomal encapsulation of mono and bis-naphthalimides. RSC pharmaceutics 1 (2) (2024)
Enric Arasanz Picher, Wahajuddin Muhammad, Stefan Barth, Julia C Chisholm, Janet Shipley, Klaus Pors
The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma. Cancers 16 (5) (2024)
Abdullahi Magaji Dauda, Thomas Swift, Richard Telford, Hend A A Abd El-Wahab, Chhanda Charan Danta, Klaus Pors, Amalia Ruiz
Insight into the liposomal encapsulation of mono and bis-naphthalimides. RSC pharmaceutics 1 (2) (2024)
Ali I M Ibrahim, Elisabet Batlle, Smarakan Sneha, Rafael Jiménez, Raquel Pequerul, Xavier Parés, Till Rüngeler, Vibhu Jha, Tiziano Tuccinardi, Maria Sadiq, Fiona Frame, Norman J Maitland, Jaume Farrés, Klaus Pors
Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer. Journal of medicinal chemistry 65 (5) (2022)
Ali I M Ibrahim, Balqis Ikhmais, Elisabet Batlle, Waed K AbuHarb, Vibhu Jha, Khaled T Jaradat, Rafael Jiménez, Raquel Pequerul, Xavier Parés, Jaume Farrés, Klaus Pors
Design, Synthesis, Biological Evaluation and In Silico Study of Benzyloxybenzaldehyde Derivatives as Selective ALDH1A3 Inhibitors. Molecules (Basel, Switzerland) 26 (19) (2021)
Smarakan Sneha, Simon C Baker, Andrew R Green, Sarah Storr, Radhika Aiyappa, Stewart Martin, Klaus Pors
Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. Biomedicines 9 (3) (2021)
Luca Quattrini, Maria Sadiq, Giovanni Petrarolo, Norman J Maitland, Fiona M Frame, Klaus Pors, Concettina La Motta
Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable Target. Biomedicines 8 (12) (2020)
Ana R N Santos, Helen M Sheldrake, Ali I M Ibrahim, Chhanda Charan Danta, Davide Bonanni, Martina Daga, Simonetta Oliaro-Bosso, Donatella Boschi, Marco Lucio Lolli, Klaus Pors
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity. MedChemComm 10 (8) (2019)

Klaus Pors.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Klaus Pors